13 / 21
Page 43
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548
Alzheimer’s and Dementia 2018
1 3
t h
W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
O
ver two billion people worldwide are estimated to suffer from a disease of the central nervous system. Over half of the people
satisfying the criteria for dementia have never received a diagnosis. In US, a lower bound of 5.7 million individuals is believed
to have Alzheimer’s disease (AD). Given this population’s reduced ability for self-assessment, it can hardly accurately report
changes in physiological state, including seizures and their causes, rendering it all the more vulnerable to undetected injury and
drug side effects which is compounded in the US drug where over 70% of the population is at least on one prescription and more
than half takes at least two thus delaying care. Given that compromised sleep is the first hallmark of AD and possibly a precursor
as sleep may be critical in reducing β-amyloid build-up. Moreover dynamic oscillations during sleep can be harnessed to identify
subtle changes in neurophysiology, tracking the fine nature of sleep in AD. Mild cognitive impairment (MCI) patients presents
a significant opportunity to address the vulnerabilities described above as well as to evaluate compounds, diets and changes
in lifestyle which may be more potent in the MCI stage than in AD. In this lecture, human-based, sleep-based, non-invasive
neurotechnology platforms will be discussed, including one specific for gathering drug response data and a sensitive one for
identifying at risk subjects. Applications of these technologies regarding other CNS disorders, including Lewy body dementia, will
be discussed.
huliang.low@bhrhospitals.nhs.ukNon-invasive home-based brain monitoring for
dementia and pre-dementia patients
Philip Steven Low
1,2
1
NeuroVigil, USA
2
Massachusetts Institute of Technology (MIT) Media Laboratory, USA
J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-003